Clinical trials

We are currently enrolling patients in the following clinical studies:

Phase 2 ALPESTRIA-1 clinical trial for Alport syndrome

We are aiming to preserve kidney function and reverse kidney damage with the investigational drug Vonafexor tested in our Phase 2 clinical study named “ALPESTRIA-1”: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome. Learn more about ALPESTRIA-1 clinical study